CELL INTELLIGENCE · 肿瘤细胞治疗研究

利用微工程化 3D 肿瘤芯片模型对靶向胶质母细胞瘤的 CAR-T 细胞进行多模态分析

Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model.

计算结构优化增强 IL13Rα2-B7-H3 串联 CAR-T 细胞以克服抗原异质性介导的肿瘤逃逸

Computational structural optimization enhances IL13Rα2 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape.

靶向 EGFR 和 IL-13Rα2 的脑室内双价 CAR-T 细胞治疗复发胶质母细胞瘤：一项 I 期试验

Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial.

胶质母细胞瘤的 CAR-T 细胞治疗：临床试验第一个十年的回顾

CAR T cell therapy for glioblastoma: A review of the first decade of clinical trials.

实体瘤免疫诊疗一体化：人 IL13Rα2 CAR-T 细胞的体内纵向追踪

Immunotheranostics in Solid Tumors: Longitudinal Tracking of Human IL13Rα2 CAR-T Cells In Vivo.

患者来源胶质母细胞瘤类器官作为实时替身评估临床 CAR-T 细胞治疗反应

Patient-derived glioblastoma organoids as real-time avatars for assessing responses to clinical CAR-T cell therapy.

携带显性负性 TGF-β 受体 II 的装甲双顺反子 CAR-T 细胞克服胶质母细胞瘤耐药

Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma.

GLUT1 过表达增强 CAR-T 细胞的代谢适应性及抗肿瘤疗效

GLUT1 overexpression enhances CAR T cell metabolic fitness and anti-tumor efficacy.

鞘内注射靶向 EGFR 和 IL13Rα2 的双价 CAR-T 细胞治疗复发性胶质母细胞瘤：I 期试验中期结果

Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results.

IL15 修饰使 CAR-T 细胞在胶质母细胞瘤中作为靶向肿瘤细胞和髓系来源抑制细胞的双重靶向剂

IL15 modification enables CAR T cells to act as a dual targeting agent against tumor cells and myeloid-derived suppressor cells in GBM.

我们证明，胶质瘤 TME 中的 MDSC 表达 IL15Ra，并且这些细胞可被分泌型 IL15 或掺入 CAR 的 IL15R 靶向部分所靶向。